Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator

Avi Sabbag, Michael Glikson, Mahmoud Suleiman, Monther Boulos, Ilan Goldenberg, Roy Beinart, Eyal Nof

Research output: Contribution to journalArticlepeer-review


Background: The clinical benefit of primary prevention implantable cardioverter-defibrillator (ICD)therapy in asymptomatic patients (New York Heart Association [NYHA]functional class I)with ischemic cardiomyopathy and left ventricular dysfunction is continually disputed. Objective: The purpose of this study was to evaluate the incidence of ventricular arrhythmias, mortality rates, and appropriate device therapies by NYHA class in a prospective national ICD registry. Methods: The study comprised 1670 consecutive patients with ischemic cardiomyopathy who were implanted with a primary prevention ICD and enrolled in the prospective national Israeli ICD Registry from 2010. The risk for clinical and arrhythmic events was assessed by NYHA class. Results: Asymptomatic patients (NYHA I)composed 19% of the study cohort. Comparison according to NYHA class showed that the highest mortality rate was in the NYHA III–IV group vs NYHA I and NYHA II (10.5% vs 5.4% and 5.8%, respectively; log rank P =.003). Conversely, cumulative incidence of appropriate ICD therapies, corrected for death as a competing risk, were higher among patients with NYHA I (11% vs 7%; P =.021). In a multivariate model, NYHA I vs ≥II remained independently associated with a significant 2-fold risk for appropriate ICD therapy (hazard ratio 2.03; 95% confidence interval 1.28–3.24). Conclusion: Our findings indicate that patients with ischemic cardiomyopathy without heart failure symptoms have a higher risk of appropriate ICD therapy compared with symptomatic patients after adjustment for the competing risk of death, suggesting possible incremental benefit of primary ICD implantation in this population.

Original languageEnglish
Pages (from-to)813-819
Number of pages7
JournalHeart Rhythm
Issue number6
StatePublished - Jun 2019
Externally publishedYes


  • Appropriate therapy
  • Competing risk
  • Defibrillator
  • Ischemic cardiomyopathy
  • Primary prevention


Dive into the research topics of 'Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator'. Together they form a unique fingerprint.

Cite this